Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics
- 1st Edition - April 9, 2024
- Author: Ting-Chao Chou
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 8 8 7 4 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 8 8 7 5 - 3
“Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics” provides a comprehensive overview and update of the mass-action law-based… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote“Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics” provides a comprehensive overview and update of the mass-action law-based unified dose-effect biodynamics, pharmacodynamics, bioinformatics, and the combination index theorem for synergy definition (MAL-BD/PD/BI/CI). Contents advocate the fundamental MAL-PD/BI/CI/BI principle for biomedical R&D, clinical trials protocol design computerized data analysis, illustrates the MAL-dynamics theory with sample analysis, and includes data entry and automated computer report print-outs. In 11 sections “Mass-Action Law Dynamics Theory and Algorithm for Translational and Precision Medicine Informatics” leads the reader from an introduction and overview, to trial protocols and MAL-PD/CI approach for biomedical R&D in vitro and in animals. It describes the current Landscape of International FDA Drug Evaluation, Clinical Pharmacology, and Clinical Trials Guidance. This is a valuable resource for biomedical researchers, healthcare professionals, and students seeking to harness the power of data informatics in precision medicine.
1. A new alternative concept for cost-effective R&D: The MALdynamics/algorithms/digital informatics
2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation
3. MAL-PD/CI approach for biomedical R&D in vitro and in animals
4. Implementation for MAL-PD Econo-Green R&D
5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance
6. The epothilone story: Experimental success and clinical failure
7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations
8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”
9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary
10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
11. Concluding remarks
Appendices
Postscript
Summary
Appendix 1. Example of two drug combination in vitro, design, execution, data analysis and CompuSyn Report printout (A + B)
Appendix 2. Example of three and two drug simultaneous combinations, design, execution, data analysis and CompuSyn Report printout (A + B + C), (A+B), (B+C) and (A+C)
Appendix 3. Example of two drug simultaneous combination in vivo (Nude mice) for: Experimental design, execution, data analysis and CompuSyn Report printout
Appendix 4. Curative Anti-Tumor Properties of Iso-oxazole-Fludelone (KOS-1803) and Fludelone (KOS 1591) Against Xenograft Tumors including multiple- drug-resisting (MDR) Tumors
Appendix 5. Notes and recommendations for MAL-PD drug evaluation in clinical trials
Appendix 6. The mass-action law system, the pattern, and combinatorial analysis. Chou TC, Ph.D. Thesis, Yale University, 1970. [338], pp 69-169
Glossary and Definitions
Research Supports
2. General dynamics principle for experimental design of all dose-effect analysis and computer simulation
3. MAL-PD/CI approach for biomedical R&D in vitro and in animals
4. Implementation for MAL-PD Econo-Green R&D
5. Digital R&D approach to international FDA drug evaluation, clinical pharmacology, and clinical trial guidance
6. The epothilone story: Experimental success and clinical failure
7. MAL-PD Advocacy: Public hearing, public comments and scientific recommendations
8. Consensus for international FDAs on definitions of “MAL-PD” and “Synergism”
9. Historical, philosophical, and mathematical analysis: Why the MAL-PD approach and the traditional approach are opposite yet complementary
10. Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
11. Concluding remarks
Appendices
Postscript
Summary
Appendix 1. Example of two drug combination in vitro, design, execution, data analysis and CompuSyn Report printout (A + B)
Appendix 2. Example of three and two drug simultaneous combinations, design, execution, data analysis and CompuSyn Report printout (A + B + C), (A+B), (B+C) and (A+C)
Appendix 3. Example of two drug simultaneous combination in vivo (Nude mice) for: Experimental design, execution, data analysis and CompuSyn Report printout
Appendix 4. Curative Anti-Tumor Properties of Iso-oxazole-Fludelone (KOS-1803) and Fludelone (KOS 1591) Against Xenograft Tumors including multiple- drug-resisting (MDR) Tumors
Appendix 5. Notes and recommendations for MAL-PD drug evaluation in clinical trials
Appendix 6. The mass-action law system, the pattern, and combinatorial analysis. Chou TC, Ph.D. Thesis, Yale University, 1970. [338], pp 69-169
Glossary and Definitions
Research Supports
- No. of pages: 438
- Language: English
- Edition: 1
- Published: April 9, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443288746
- eBook ISBN: 9780443288753
TC
Ting-Chao Chou
Born in Taiwan, Ting-Chao (David) Chou received his Ph.D. in Pharmacology from Yale University and completed his Post-Doctoral Fellowship at Johns Hopkins University School of Medicine. He joined Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and became a Member and Professor of Pharmacology at Cornell University Graduate School of Medical Sciences in 1988. He retired from MSKCC in 2013 and founded PD Science LLC. Professor Chou was elected to the Membership of The Johns Hopkins Society of Scholars, induced by the President of JHU on April 8, 2019, among 16 national and international inductees. Dr. Chou’s published 375 papers have garnered over forty thousand hundred citations with an h-index of 75 and i10-index of 290. He is the inventor/co-inventor of 40 U.S. patents. Currently, he advocates for MAL-based digital biomedical R&D for translational medicine bioinformatics (BI) to provide a complementary alternative basic framework to the traditional statistics-based R&D
Affiliations and expertise
PD Science LLC